Overview of Functional Capacity and Quality of Life of Chronic Obstructive Pulmonary Disease (COPD) Patients
Downloads
Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of morbidity and mortality worldwide, with a significant impact on patients’ functional capacity and quality of life. This study aims to describe the functional capacity and quality of life of COPD patients at Prof. Dr. Chairuddin P. Lubis Hospital. This study is a descriptive observational study with a serial case design. The research subjects were stable COPD patients who met the inclusion and exclusion criteria, using a convenience sampling technique. Data collected included demographic characteristics, inhaled bronchodilator therapy, functional capacity measured using spirometry and the six-minute walking distance (6MWD) test, and quality of life assessed using mMRC and CAT scores. Statistical analysis was performed using descriptive methods. A total of 110 patients participated in the study; the majority were aged 60–69 years (69.6%) and male (78%). Mean FEV?/FVC, FEV?, FVC, and 6MWD scores were higher in the tiotropium group compared with the indacaterol/glycopyrronium group. The mean CAT score indicated slightly worse quality of life in the indacaterol/glycopyrronium group (10.9 vs. 9.9). The majority of patients had cardiovascular-related comorbidities (20.9%). Tiotropium therapy showed better results in functional capacity compared with indacaterol/glycopyrronium, while quality of life was influenced by COPD severity and comorbidities. A holistic management approach that includes comorbidity management and patient education is needed to improve prognosis and quality of life. Further research is needed to explore the relationship between therapy and clinical outcomes.
Agrawal, R., Moghtader, S., Ayyala, U., Bandi, V., & Sharafkhaneh, A. (2019). Update on management of stable chronic obstructive pulmonary disease. Journal of Thoracic Disease, 11(Suppl. 17), S1800–S1809. https://doi.org/10.21037/jtd.2019.06.12
Agustí, A., & Hogg, J. C. (2019). Update on the pathogenesis of chronic obstructive pulmonary disease. New England Journal of Medicine, 381(13), 1248–1256.
Beeh, K. M., Derom, E., Kanniess, F., et al. (2011). Indacaterol, a novel once-daily long-acting ?2-agonist, provides sustained bronchodilation and symptom relief in patients with COPD. Chest, 140(1), 68–75.
Boers, E., Barrett, M., Su, J. G., et al. (2023). Global burden of chronic obstructive pulmonary disease through 2050. JAMA Network Open, 6(12), e2346598. https://doi.org/10.1001/jamanetworkopen.2023.46598
Buhl, R., Gessner, C., Schuermann, W., et al. (2015). Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): A randomised, non-inferiority study. Thorax, 70(4), 311–319. https://doi.org/10.1136/thoraxjnl-2014-206345
Celli, B. R., & MacNee, W. (2004). Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. European Respiratory Journal, 23(6), 932–946.
Global Initiative for Chronic Obstructive Lung Disease. (2023). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2023 report. https://goldcopd.org/
Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report. https://goldcopd.org/
Hashimoto, S., Ikeuchi, H., Murata, S., Kitawaki, T., Ikeda, K., & Banerji, D. (2016). Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: A subgroup analysis from the SHINE study. International Journal of Chronic Obstructive Pulmonary Disease, 11, 2543–2551. https://doi.org/10.2147/COPD.S111408
Holland, A. E., Spruit, M. A., Troosters, T., et al. (2014). An official European Respiratory Society/American Thoracic Society technical standard: Field walking tests in chronic respiratory disease. European Respiratory Journal, 44(6), 1428–1446.
Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., & Leidy, N. K. (2009). Development and first validation of the COPD Assessment Test. European Respiratory Journal, 34(3), 648–654.
Kaplan, A., Chapman, K. R., Anees, S. M., et al. (2019). Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: The POWER study. International Journal of Chronic Obstructive Pulmonary Disease, 14, 249–260. https://doi.org/10.2147/COPD.S185485
Lee, J. H., et al. (2021). Effects of tiotropium and indacaterol/glycopyrronium on physical activity and quality of life in patients with moderate-to-severe COPD. International Journal of Chronic Obstructive Pulmonary Disease, 16, 1923–1931.
Lee, S. H., Rhee, C. K., Yoo, K., et al. (2021). Direct switch from tiotropium to indacaterol/glycopyrronium in chronic obstructive pulmonary disease patients in Korea. Tuberculosis and Respiratory Diseases, 84(2), 96–104. https://doi.org/10.4046/trd.2020.0109
Lim, J. U., Lee, J. H., Kim, J. S., et al. (2017). Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease, 12, 2465–2475. https://doi.org/10.2147/COPD.S141295
Maltais, F., Ferguson, G. T., Feldman, G., et al. (2010). A randomized, double-blind study of once-daily tiotropium in patients with moderate COPD. European Respiratory Journal, 36(4), 736–743.
Miravitlles, M., et al. (2011). COPD management: Role of symptom assessment in routine clinical practice. International Journal of Chronic Obstructive Pulmonary Disease, 6, 173–183. https://doi.org/10.2147/COPD.S16655
Miravitlles, M., Matsunaga, K., & Dreher, M. (2023). Stepwise management of COPD: What is next after bronchodilation? Therapeutic Advances in Respiratory Disease, 17, 1–15. https://doi.org/10.1177/17534666231208630
Mulyana, H. (2019). Penyakit paru obstruktif kronik. Dalam Buku ajar ilmu penyakit dalam (Edisi ke-7, hlm. 551–554). Interna Publishing.
Sholihah, M., Suradi, S., & Aphridasari, J. (2019). The effects of quercetin on interleukin (IL-8) serum, %forced expiratory volume in one second (FEV1), and COPD Assessment Test (CAT) scores in stable chronic obstructive pulmonary disease (COPD) patients. Jurnal Respirologi Indonesia, 39(2), 103–112. https://doi.org/10.36497/jri.v39i2.51
Singh, D., Agusti, A., Anzueto, A., et al. (2019). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019. European Respiratory Journal, 53(5). https://doi.org/10.1183/13993003.00164-2019
Solehati, T., Rahmat, A., & Kosasih, C. E. (2019). Relation of media on adolescents’ reproductive health attitude and behaviour. Jurnal Penelitian Komunikasi dan Opini Publik, 23(1). https://doi.org/10.33299/jpkop.23.1.1768
Tamondong-Lachica, D. R., Skolnik, N., Hurst, J. R., et al. (2023). GOLD 2023 update: Implications for clinical practice. International Journal of Chronic Obstructive Pulmonary Disease, 18, 745–754. https://doi.org/10.2147/COPD.S404690
Vogelmeier, C. F., et al. (2013). Efficacy and safety of once-daily QVA149 compared with the free combination of its monocomponents indacaterol and glycopyrronium in patients with COPD: The BEACON study. International Journal of Chronic Obstructive Pulmonary Disease, 8, 501–508. https://doi.org/10.2147/COPD.S48503
Vogelmeier, C. F., Gaga, M., Aalamian-Mattheis, M., et al. (2017). Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: The CRYSTAL open-label randomised trial. Respiratory Research, 18(1), 1–9. https://doi.org/10.1186/s12931-017-0622-x
Wedzicha, J. A., Banerji, D., Chapman, K. R., et al. (2016). Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. New England Journal of Medicine, 374(23), 2222–2234. https://doi.org/10.1056/NEJMoa1516385
Yawn, B. P., Mintz, M. L., & Doherty, D. E. (2021). GOLD in practice: Chronic obstructive pulmonary disease treatment and management in the primary care setting. International Journal of Chronic Obstructive Pulmonary Disease, 16, 289–299. https://doi.org/10.2147/COPD.S222664
Zhang, Y., Wang, L., Mutlu, G. M., & Cai, H. (2021). More to explore: Further definition of risk factors for COPD—Differential gender difference, modest elevation in PM2.5, and e-cigarette use. Frontiers in Physiology, 12, 669152. https://doi.org/10.3389/fphys.2021.669152
Copyright (c) 2026 Rizki Rahmadani Dalimunthe, Pandiaman Pandia, Amira Permatasari Tarigan, Putri Eyanoer

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.



